Fulcrum Therapeutics, Inc. (FULC) Securities Fraud Investigation - Levi & Korsinsky

Fulcrum Therapeutics, Inc. stock lost roughly half its value after the FDA flagged class-wide safety concerns about the entire PRC2 inhibitor drug class -- forcing immediate discontinuation of pociredicr and a full strategic review. NEW YORK, June 9, 2026 /PRNewswire/ -- Fulcrum Therapeutics, Inc. (NASDAQ: FULC) shares fell approximately 50% on June 1, 2026, after the company disclosed that the FDA had raised safety concerns about PRC2 inhibition.

PRNewsWire • Jun 9, 2026

Levi & Korsinsky Announces Investigation of Securities Claims Against Fulcrum Therapeutics, Inc. (FULC)

Fulcrum Therapeutics, Inc. stock lost roughly half its value in a single session after the company disclosed FDA safety concerns that forced discontinuation of its lead sickle-cell candidate Fulcrum Therapeutics, Inc. stock lost roughly half its value in a single session after the company disclosed FDA safety concerns that forced discontinuation of its lead sickle-cell candidate

GlobeNewsWire • Jun 5, 2026

Fulcrum Therapeutics (FULC) Loses 51% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Fulcrum Therapeutics (FULC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Investment Research • Jun 5, 2026

What's Going On With Fulcrum Therapeutics Stock On Thursday?

Fulcrum Therapeutics Inc. (NASDAQ:FULC) shares are up on Thursday as the company faces significant challenges following its decision to discontinue pociredir, its lead experimental drug for sickle cell disease.

Benzinga • Jun 4, 2026

FULC Investor Alert: Levi & Korsinsky Investigates Fulcrum Therapeutics, Inc. (FULC) for Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--Shareholders of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) saw the stock plunged roughly 50% on June 1, 2026, following disclosure of an FDA safety concerns related to the PRC2 inhibitor drug class. Those who lost money on FULC are encouraged to submit their information immediately. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. The single-session collapse followed Fulcrum's June 1, 2026 Form 8-K, which.

Business Wire • Jun 4, 2026

FULC SHAREHOLDER INVESTIGATION: SueWallSt Investigates Fulcrum Therapeutics, Inc. for Possible Securities Law Violations

SEC filings reflected insider equity holdings and awards totaling more than 264,000 shares NEW YORK, June 3, 2026 /PRNewswire/ -- Fulcrum Therapeutics, Inc. (NASDAQ: FULC) lost approximately 50% of its value in a single session after disclosing on June 1, 2026, that the FDA had raised class-wide safety concerns about PRC2-targeting agents, leading the Company to discontinue the program of its lead candidate pociredir. Shareholders who lost money on their FULC investment are encouraged to submit their information here.

PRNewsWire • Jun 3, 2026

FULC Stock Crashes as Cancer Risk Forces Its Only Drug Program's End

Fulcrum Therapeutics stock sinks 51% after ending pociredir development in SCD due to FDA cancer-risk concerns, leaving no clinical-stage assets.

Zacks Investment Research • Jun 3, 2026

Fulcrum plummets 50% after scrapping lead sickle-cell drug on FDA concerns

Shares of Fulcrum Therapeutics plunged 50% in premarket trading on Tuesday after the company said it would abandon development of its experimental sickle-cell disease drug following cancer-risk ​concerns raised by the U.S. FDA, and explore strategic options ‌including a potential sale or merger.

Reuters • Jun 2, 2026

FULC INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Fulcrum Therapeutics, Inc.

ATLANTA, June 02, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Fulcrum Therapeutics, Inc. (“Fulcrum” or the “Company”) (NASDAQ: FULC) complied with federal securities laws. On June 1, 2026, Fulcrum announced the discontinuation of its pociredir program for the treatment of sickle cell disease. The price of the Company's stock dropped following this news.

GlobeNewsWire • Jun 2, 2026

Fulcrum Therapeutics, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Fulcrum Therapeutics, Inc. (FULC)

Fulcrum Therapeutics, Inc. guided investors toward a Phase III future for pociredir while a $25.1 million facility lease locked the company into infrastructure now stranded by program termination. NEW YORK, June 2, 2026 /PRNewswire/ -- Fulcrum Therapeutics, Inc. (NASDAQ: FULC) shareholders saw a roughly 50% single-session collapse after the company disclosed on June 1, 2026 that FDA safety concerns forced immediate discontinuation of pociredir and triggered a strategic review.

PRNewsWire • Jun 2, 2026